Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.83 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.83 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.83 |
| ▸ | TNF | P01375 | 9/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848579 | 0.91 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637167 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4847439 | 0.91 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637688 | 0.90 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4850888 | 0.89 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3127985 | 0.88 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4925142 | 0.88 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3131798 | 0.88 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537107 | 0.88 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4926271 | 0.87 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1510518-B1 | Substituted 1,3,4-oxadiazoles for use in the treatement or prophylaxis of diseases | CELGENE CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1462449-B9 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORP (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-1462449-B1 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7091356-B2 | Substituted alkanohydroxamic acids and method of reducing TNFα levels | CELGENE CORPORATION | 2006-08-15 | — | — | US | disclosed |
| EP-1510518-A2 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORPORATION (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1242413-B1 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1462449-A1 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORPORATION (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2004-01-08 | — | — | US | disclosed |
| EP-1242413-A4 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1242413-A1 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6326388-B1 | ANTIINFLAMMATORY AGENTS | CELGENE CORPORATION | 2001-12-04 | — | — | US | disclosed |
| WO-2001046183-A1 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | TNF, TNFRSF1A, LTA | PDE4A 10/4885PDE4B 54/4885PDE4C 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.